Article
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Diagnostic microbiology and infectious disease - 1 Dec 2003
Garrison Mark W, Schimmels Julie A, Madaras-Kelly Karl J
Abstract excerpt
An in vitro pharmacodynatnic modeling apparatus (PDMA) generated specific bacterial kill profiles for single-dose regimens of gatifloxacin (GT), gemifloxacin (GM), moxifloxacin (MX) and levofloxacin (LV) against isolates of Streptococcus pneumoniae with specific QRDR profiles: SP-WT (no modifications); SP-C (changes in parC); and SP-AC (changes in both parC and gyrA). No differences in 3-log reduction time or...
Topics
- Analysis of Variance
- Aza Compounds
- Culture Media
- DNA Gyrase
- DNA Topoisomerase IV
- Drug Resistance, Bacterial
- Fluoroquinolones
- Gatifloxacin
- Gemifloxacin
- Humans